February 20, 2018
Many people were glued to their television sets during February, cheering on our Winter Olympians. Meanwhile, the team across MIMS Asia Pacific has developed a new clinical decision support module suitable for screening of drugs banned in sports based on the World Anti-Doping Agency (WADA) Prohibited Drugs List. This latest feature equips physicians with access to reliable drug information critical to help athletes avoid inadvertent positive results from using medications that contain prohibited substances.
The new enhancement in the MIMS Clinical Decision Support System provides added value to national sports committees and athlete management organisations, particularly during sporting events. It is currently available in English and was made available in Korean.
MIMS has been historically known for its drug reference publications. In recent times, I have commented in our MIMS Matters newsletters that MIMS has evolved to develop progressive digital solutions to empower doctors and healthcare communities to improve patient outcomes across the Asia Pacific region. We are excited to contribute to healthcare technology that is integral to help world class athletes achieve peak performance, reduce risk of injuries and avoid medication misadventures when it matters most.